These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 36185183

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience.
    Autore F, Chiusolo P, Sorà F, Giammarco S, Laurenti L, Innocenti I, Metafuni E, Piccirillo N, Pagano L, Sica S.
    Front Oncol; 2021; 11():614721. PubMed ID: 34336637
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia.
    Song YH, Peng P, Qiao C, Zhang R, Li JY, Lu H.
    Onco Targets Ther; 2017; 10():4917-4924. PubMed ID: 29062237
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. UK Experience of an Alternative ATO Dosing Regimen in APL.
    Russell N, Dillon R.
    Front Oncol; 2020; 10():594129. PubMed ID: 33262951
    [Abstract] [Full Text] [Related]

  • 30. [Analysis of early death factors and prognosis of acute promyelocytic leukemia].
    Wu YX, Wu DP, Chen SN, Qiu HY, Han Y, Li CX, Ma X, Sun AN, Tang XW, Hu XH.
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec 14; 41(12):1025-1030. PubMed ID: 33445851
    [Abstract] [Full Text] [Related]

  • 31. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    Yang MH, Wan WQ, Luo JS, Zheng MC, Huang K, Yang LH, Mai HR, Li J, Chen HQ, Sun XF, Liu RY, Chen GH, Feng X, Ke ZY, Li B, Tang YL, Huang LB, Luo XQ.
    Am J Hematol; 2018 Dec 14; 93(12):1467-1473. PubMed ID: 30160789
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
    Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, Ghahremani MH.
    Ann Oncol; 2010 Sep 14; 21(9):1884-1890. PubMed ID: 20164150
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Min GJ, Cho BS, Park SS, Park S, Jeon YW, Yahng SA, Shin SH, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim HJ.
    Ann Hematol; 2020 May 14; 99(5):973-982. PubMed ID: 32270215
    [Abstract] [Full Text] [Related]

  • 38. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, Liu X, Han X, Hu L, Wang S, Zhao Y, Zhang Y, Fan S, Lv C, Li L, Zhu L.
    Blood; 2010 Mar 04; 115(9):1697-702. PubMed ID: 20029047
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.